Metformin Treatment in Progressive Multiple Sclerosis

Description

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Conditions

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

A Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple Sclerosis

Metformin Treatment in Progressive Multiple Sclerosis

Condition
Secondary Progressive Multiple Sclerosis
Intervention / Treatment

-

Contacts and Locations

Los Angeles

University of California, Los Angeles, Los Angeles, California, United States, 90095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patient signed informed consent.
  • 2. Age 30-65
  • 3. Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple Sclerosis as defined by the 2017 McDonald Criteria
  • 4. Intent to maintain current MS disease modifying treatment through the trial duration
  • 1. Clinical relapse in prior 12 months
  • 2. New T2 lesion or gadolinium enhancing lesion in prior 12 months
  • 3. Glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment
  • 4. Changes in disease modifying therapy in prior three months
  • 5. Plans to change current disease modifying therapy
  • 6. Contraindication to MRI, inability to tolerate MRI
  • 7. Use of metformin for any other indication
  • 8. Renal dysfunction (GFR \< 60)
  • 9. Hepatic dysfunction (AST or ALT \> 1.5 x upper limit of normal)
  • 10. B12 deficiency
  • 11. Prior poor reaction to metformin
  • 12. Congestive heart failure
  • 13. Alcohol abuse
  • 14. Metabolic acidosis
  • 15. Females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment
  • 16. Concomitant use of drugs with drug-drug interactions with metformin
  • 17. Previous adverse effect with metformin treatment

Ages Eligible for Study

30 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of California, Los Angeles,

Kevin R Patel, MD, PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

2026-05-26